Insider · CIK 0001970033
Paul Reider
officer
Files at CHRS (Coherus Oncology, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 20, 2025 | CHRS Coherus Oncology, Inc. | FTax withholding Common Stock | -4,858 | $1.39 | $6,753 | 82,069 | Jan 22, 2025 |
| Jan 4, 2025 | CHRS Coherus Oncology, Inc. | FTax withholding Common Stock | -2,277 | $1.66 | $3,780 | 86,927 | Jan 7, 2025 |
| Jan 3, 2025 | CHRS Coherus Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Jan 7, 2025 |
| Dec 13, 2024 | CHRS Coherus Oncology, Inc. | FTax withholding Common Stock | -2,073 | $1.61 | $3,338 | 89,204 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.